|
1
|
Darzynkiewicz Z, Carter SP, Mikulski SM,
Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of Pannon
(P-30 protein), a novel anticancer agent. Cell Tissue Kinet.
21:169–182. 1988.PubMed/NCBI
|
|
2
|
Mosimann SC, Ardelt W and James MN:
Refined 1.7 A X-ray crystallographic structure of P-30 protein, an
amphibian ribonuclease with anti-tumor activity. J Mol Biol.
236:1141–1153. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ardelt W, Mikulski SM and Shogen K: Amino
acid sequence of an anti-tumor protein from Rana pipiens oocytes
and early embryos. Homology to pancreatic ribonucleases. J Biol
Chem. 266:245–251. 1991.PubMed/NCBI
|
|
4
|
Gorbatyuk VY, Tsai CK, Chang CF and Huang
TH: Effect of N-terminal and Met23 mutations on the structure and
dynamics of onconase. J Biol Chem. 279:5772–5780. 2004. View Article : Google Scholar
|
|
5
|
Bretscher LE, Abel RL and Raines RT: A
ribonuclease A variant with low catalytic activity but high
cytotoxicity. J Biol Chem. 275:9893–9896. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu Y, Mikulski SM, Ardelt W, Rybak SM and
Youle RJ: A cytotoxic ribonuclease. Study of the mechanism of
onconase cytotoxicity. J Biol Chem. 268:10686–10693.
1993.PubMed/NCBI
|
|
7
|
Saxena SK, Sirdeshmukh R, Ardelt W,
Mikulski SM, Shogen K and Youle RJ: Entry into cells and selective
degradation of tRNAs by a cytotoxic member of the RNase A family. J
Biol Chem. 277:15142–15146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suhasini AN and Sirdeshmukh R: Transfer
RNA cleavages by onconase reveal unusual cleavage sites. J Biol
Chem. 281:12201–12209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodríguez M, Torrent G, Bosch M, Rayne F,
Dubremetz JF, Ribó M, Benito A, Vilanova M and Beaumelle B:
Intracellular pathway of onconase that enables its delivery to the
cytosol. J Cell Sci. 120:1405–1411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Newton DL, Hansen HJ, Mikulski SM,
Goldenberg DM and Rybak SM: Potent and specific antitumor effects
of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the
treatment of non-Hodgkin lymphoma. Blood. 97:528–535. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pavlakis N and Vogelzang NJ: Ranpirnase -
an antitumour ribonuclease: Its potential role in malignant
mesothelioma. Expert Opin Biol Ther. 6:391–399. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee I, Kalota A, Gewirtz AM and Shogen K:
Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549
human lung cancer xenografts of nude mice. Anticancer Res.
27:299–307. 2007.PubMed/NCBI
|
|
13
|
Chang CH, Gupta P, Michel R, Loo M, Wang
Y, Cardillo TM and Goldenberg DM: Ranpirnase (frog RNase) targeted
with a humanized, internalizing, anti-Trop-2 antibody has potent
cytotoxicity against diverse epithelial cancer cells. Mol Cancer
Ther. 9:2276–2286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu XF and Xing PX: Discovery and
validation of new molecular targets for ovarian cancer. Curr Opin
Mol Ther. 5:625–630. 2003.
|
|
15
|
Ménard S, Pupa SM, Campiglio M and
Tagliabue E: Biologic and therapeutic role of HER2 in cancer.
Oncogene. 22:6570–6578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Snyder EL, Saenz CC, Denicourt C, Meade
BR, Cui XS, Kaplan IM and Dowdy SF: Enhanced targeting and killing
of tumor cells expressing the CXC chemokine receptor 4 by
transducible anticancer peptides. Cancer Res. 65:10646–10650. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saar K, Lindgren M, Hansen M, Eiríksdóttir
E, Jiang Y, Rosenthal-Aizman K, Sassian M and Langel U:
Cell-penetrating peptides: A comparative membrane toxicity study.
Anal Biochem. 345:55–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu S, Tager LA, Chitale S and Riley LW: A
cell-penetrating peptide derived from mammalian cell uptake protein
of Mycobacterium tuberculosis. Anal Biochem. 353:7–14. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Snyder EL and Dowdy SF: Cell penetrating
peptides in drug delivery. Pharm Res. 21:389–393. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rhee M and Davis P: Mechanism of uptake of
C105Y, a novel cell-penetrating peptide. J Biol Chem.
281:1233–1240. 2006. View Article : Google Scholar
|
|
22
|
Watkins CL, Brennan P, Fegan C, Takayama
K, Nakase I, Futaki S and Jones AT: Cellular uptake, distribution
and cytotoxicity of the hydrophobic cell penetrating peptide
sequence PFVYLI linked to the proapoptotic domain peptide PAD. J
Control Release. 140:237–244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JW, Bang EK, Jeon EM and Kim BH:
Complexation and conjugation approaches to evaluate siRNA delivery
using cationic, hydrophobic and amphiphilic peptides. Org Biomol
Chem. 10:96–102. 2012. View Article : Google Scholar
|
|
24
|
Macauley-Patrick S, Fazenda ML, McNeil B
and Harvey LM: Heterologous protein production using the Pichia
pastoris expression system. Yeast. 22:249–270. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Damasceno LM, Huang CJ and Batt CA:
Protein secretion in Pichia pastoris and advances in protein
production. Appl Microbiol Biotechnol. 93:31–39. 2012. View Article : Google Scholar
|
|
26
|
Sinha J, Plantz BA, Inan M and Meagher MM:
Causes of proteolytic degradation of secreted recombinant proteins
produced in methylotrophic yeast Pichia pastoris: Case study with
recombinant ovine interferontau. Biotechnol Bioeng. 89:102–112.
2005. View Article : Google Scholar
|
|
27
|
Vassileva A, Chugh DA, Swaminathan S and
Khanna N: Expression of hepatitis B surface antigen in the
methylotrophic yeast Pichia pastoris using the GAP promoter. J
Biotechnol. 88:21–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Sun Y, Ke F, Zhao H, Liu T, Xu L,
Liu Y and Yan Y: Constitutive expression of yarrowia lipolytica
lipase LIP2 in Pichia pastoris using GAP as promoter. Appl Biochem
Biotechnol. 166:1355–1367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pedersen MW, Jacobsen HJ, Koefoed K, Hey
A, Pyke C, Haurum JS and Kragh M: Sym004: A novel synergistic
anti-epidermal growth factor receptor antibody mixture with
superior anticancer efficacy. Cancer Res. 70:588–597. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Q, Villeneuve G and Wang Z: Control
of epidermal growth factor receptor endocytosis by receptor
dimerization, rather than receptor kinase activation. EMBO Rep.
6:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan Z, Lu Y, Wu X and Mendelsohn J:
Antibody-induced epidermal growth factor receptor dimerization
mediates inhibition of autocrine proliferation of A431 squamous
carcinoma cells. J Biol Chem. 269:27595–27602. 1994.PubMed/NCBI
|
|
32
|
Perez-Torres M, Guix M, Gonzalez A and
Arteaga CL: Epidermal growth factor receptor (EGFR) antibody
down-regulates mutant receptors and inhibits tumors expressing EGFR
mutations. J Biol Chem. 281:40183–40192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vasandani VM, Burris JA and Sung C:
Reversible nephrotoxicity of onconase and effect of lysine pH on
renal onconase uptake. Cancer Chemother Pharmacol. 44:164–169.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mikulski S, Grossman A, Carter P, Shogen K
and Costanzi J: Phase-I human clinical-trial of onconase(r) (p-30
protein) administered intravenously on a weekly schedule in
cancer-patients with solid tumors. Int J Oncol. 3:57–64.
1993.PubMed/NCBI
|
|
35
|
Vasandani VM, Wu YN, Mikulski SM, Youle RJ
and Sung C: Molecular determinants in the plasma clearance and
tissue distribution of ribonucleases of the ribonuclease A
superfamily. Cancer Res. 56:4180–4186. 1996.PubMed/NCBI
|
